Results 151 to 160 of about 295,251 (340)

Enhancing End Stage Renal Disease Outcome Prediction: A Multi-Sourced Data-Driven Approach [PDF]

arXiv
Objective: To improve prediction of Chronic Kidney Disease (CKD) progression to End Stage Renal Disease (ESRD) using machine learning (ML) and deep learning (DL) models applied to an integrated clinical and claims dataset of varying observation windows, supported by explainable AI (XAI) to enhance interpretability and reduce bias.
arxiv  

Continuous Arterio-venous Hemofiltration in a Wearable Device to Treat End-stage Renal Disease

, 1986
A Murisasco, J.P. Reynier, A. RAGON, Y. Boobes, M. Baz, C Durand, Philippe Bertocchio, C. AGENET, Mehdi Maanaoui   +8 more
openalex   +1 more source

The Medicare End-Stage Renal Disease Program [PDF]

, 1991
Norman G. Levinsky, Richard A. Rettig
openalex   +1 more source

Mechanisms and Therapeutic Strategies for Minority Cell‐Induced Paclitaxel Resistance and Tumor Progression Mediated by Mechanical Forces

Advanced Science, EarlyView.
This study provides new perspectives into the interactions between mechanical forces and cellular dynamics within the tumor microenvironment, particularly elucidating how minority Paclitaxel‐resistant cancer cells (MRCs) promote tumor progression and treatment resistance through mechanical forces and also providing effective treatment strategies for ...
Xueyan Feng, Di Zhang, Guoxun Wang, Liwei Lu, Feng Feng, Xiuyu Wang, Chanchan Yu, Yahong Chai, Jin Zhang, Wenchao Li, Jing Liu, Hongxia Sun, Li Yao   +12 more
wiley   +1 more source

Epidemiologic features of treated end-stage renal disease in a large prepaid health plan. [PDF]

, 1990
Juan D. Ordoñez, Robert A. Hiatt, C. P. Quesenberry   +2 more
openalex   +1 more source

STING Agonists and How to Reach Their Full Potential in Cancer Immunotherapy

Advanced Science, EarlyView.
STING agonists show promise in preclinical studies in boosting an anti‐tumor response using the immune system. However, different limitations remain, and future research is needed to better understand how STING activation impacts the tumor microenvironment, identify effective combination strategies, and determine the best tumor types for STING agonist ...
Laura Gehrcken, Christophe Deben, Evelien Smits, Jonas R.M. Van Audenaerde   +3 more
wiley   +1 more source

Shoshin beriberi in an AIDS patient with end‐stage renal disease [PDF]

, 1992
John Bright Cage, Barry M. Wall
openalex   +1 more source

Smart Organic–Inorganic Copolymer Nanoparticles Distinguish Between Microglia and Cancer Cells for Synergistic Immunotherapy in Glioma

Advanced Science, EarlyView.
The tumor microenvironment‐responsive nanoagonists are developed using an organic–inorganic copolymer composed of the polymer (PC6AB) and manganous phosphate ionic oligomers (MnP). PC6AB with membranolytic activity selectively interacts with tumor cell membranes to induce immunogenic cell death, while MnP activates the STING pathway in immune cells ...
Shiming Zhang, Kun Shang, Lidong Gong, Qian Xie, Jianfei Sun, Meng Xu, Xunbin Wei, Zhaoheng Xie, Xinyu Liu, Hao Tang, Zhengren Xu, Wei Wang, Haihua Xiao, Zhiqiang Lin, Hongbin Han   +14 more
wiley   +1 more source

The INAVA mRNA in Extracellular Vesicles Activates Normal Ovarian Fibroblasts by Phosphorylation–Ubiquitylation Crosstalk of HMGA2

Advanced Science, EarlyView.
Ovarian cancer‐derived extracellular vesicles (EVs) transfer INAVA mRNA to normal ovarian fibroblasts (NOFs). Translated INAVA protein inhibits HMGA2 phosphorylation‐dependent ubiquitylation and proteasomal degradation, promoting NOF activation.
Lingkai Gu, Zhangjin Shen, Shizhen Shen, Conghui Wang, Yuwan Liu, Xinyi Wei, Mengxia Zheng, Jiaxin Gu, Xiaojing Chen, Yi Sun, Junfen Xu, Yan Lu, Weiguo Lu   +12 more
wiley   +1 more source

Extracellular Matrix Targeted MRI Probes

Analysis &Sensing, Volume 3, Issue 1, January 2023., 2023
Gadolinium based MRI probes targeted to ECM components, either proteins or enzymes, hold promise for accurate molecular characterization and staging of fibrotic diseases in vivo. Non‐covalent binding probes (1), reactive probes (2), and enzyme‐responsive probes (3) are discussed.
Giuseppe Digilio, Sara Lacerda, Begoña Lavin Plaza, Alkystis Phinikaridou   +3 more
wiley   +1 more source